| Autor: |
Amadea Britton, Peter J. Embi, Matthew E. Levy, Manjusha Gaglani, Malini B. DeSilva, Brian E. Dixon, Kristin Dascomb, Palak Patel, Kristin E. Schrader, Nicola P. Klein, Toan C. Ong, Karthik Natarajan, Emily Hartmann, Anupam B. Kharbanda, Stephanie A. Irving, Monica Dickerson, Margaret M. Dunne, Chandni Raiyani, Shaun J. Grannis, Edward Stenehjem, Ousseny Zerbo, Suchitra Rao, Jungmi Han, Chantel Sloan-Aagard, Eric P. Griggs, Zachary A. Weber, Kempapura Murthy, William F. Fadel, Nancy Grisel, Charlene McEvoy, Ned Lewis, Michelle A. Barron, Juan Nanez, Sarah E. Reese, Mufaddal Mamawala, Nimish R. Valvi, Julie Arndorfer, Kristin Goddard, Duck-Hye Yang, Bruce Fireman, Sarah W. Ball, Ruth Link-Gelles, Allison L. Naleway, Mark W. Tenforde |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
MMWR. Morbidity and mortality weekly report. 71(42) |
| ISSN: |
1545-861X |
| Popis: |
Persons with moderate-to-severe immunocompromising conditions might have reduced protection after COVID-19 vaccination, compared with persons without immunocompromising conditions (1-3). On August 13, 2021, the Advisory Committee on Immunization Practices (ACIP) recommended that adults with immunocompromising conditions receive an expanded primary series of 3 doses of an mRNA COVID-19 vaccine. ACIP followed with recommendations on September 23, 2021, for a fourth (booster) dose and on September 1, 2022, for a new bivalent mRNA COVID-19 vaccine booster dose, containing components of the BA.4 and BA.5 sublineages of the Omicron (B.1.1.529) variant (4). Data on vaccine effectiveness (VE) of monovalent COVID-19 vaccines among persons with immunocompromising conditions since the emergence of the Omicron variant in December 2021 are limited. In the multistate VISION Network |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
